Gynecologic oncology reports
Audio Summaries

Interval debulking with HIPEC in patient with VP shunt

Aug 8, 2026

The authors investigate the safety and feasibility of administering hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with an indwelling ventriculoperitoneal (VP) shunt, a scenario previously unreported in the literature. They present a case where a multidisciplinary approach allowed for successful interval debulking surgery with HIPEC, demonstrating that this treatment can be safely performed without complications in such patients. This finding suggests that HIPEC may be a viable option for ovarian cancer patients with VP shunts, potentially expanding their treatment possibilities.

Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib

Aug 8, 2026

The authors aim to highlight the potential of targeting rare molecular alterations, specifically the ALK-DCTN1 fusion, in advanced uterine leiomyosarcoma (uLMS) to improve treatment outcomes. They present a case of a 59-year-old woman with stage IV uLMS who achieved significant tumor regression and durable partial remission after treatment with the ALK inhibitor ceritinib, following multiple failed conventional therapies. This case emphasizes the critical role of comprehensive molecular profiling in identifying actionable targets for effective treatment in aggressive malignancies like uLMS.

Primary ovarian synovial sarcoma in an adolescent mimicking a germ cell tumor: A case report and diagnostic challenge

Aug 5, 2026

The authors aim to highlight the diagnostic challenges posed by primary ovarian synovial sarcoma, a rare malignancy that can mimic more common ovarian tumors like germ cell neoplasms in adolescents. They present a case of a 14-year-old girl with a complex adnexal mass, emphasizing the importance of integrating histopathological and immunohistochemical findings for accurate diagnosis, particularly when molecular testing is not available. The study underscores the aggressive nature of this tumor and the critical need for awareness among clinicians to ensure timely and accurate diagnosis.

Malignant transformation of mature ovarian teratoma into goblet cell adenocarcinoma: a case report

Jul 28, 2026

This case report investigates the rare malignant transformation of a mature ovarian teratoma into goblet cell adenocarcinoma, a condition with undefined optimal management strategies. The authors present the clinical course of a 39-year-old woman and discuss the challenges in treatment, advocating for a histology-directed approach that aligns with gastrointestinal cancer therapies rather than traditional gynecologic regimens. They emphasize the need for further collaborative reporting to establish standardized treatment guidelines for this uncommon tumor type.

Quality of life and psychological outcomes with albumin-bound paclitaxel-carboplatin versus solvent-based paclitaxel-carboplatin as first-line chemotherapy in stage IC-IV ovarian carcinoma

Jul 28, 2026

The authors aim to evaluate the impact of albumin-bound paclitaxel-carboplatin versus solvent-based paclitaxel-carboplatin on quality of life and psychological outcomes in patients with stage IC-IV ovarian carcinoma. Using the EORTC QLQ-OV28 and Hamilton Depression Rating Scale, they conduct a secondary analysis of a randomized controlled trial to assess these factors over a 12-month period.

A rare case of uterine carcinosarcoma presenting as complete uterine inversion: A case report

Jul 26, 2026

This case report explores the rare occurrence of complete uterine inversion caused by endometrial carcinosarcoma in an 80-year-old woman. The authors aim to highlight the surgical challenges associated with this condition and demonstrate that hysterectomy can be safely performed without correcting the inversion. The findings underscore the need for awareness of this unusual presentation in gynecologic malignancies.

Leading the way: A national mixed-methods survey of race, ethnicity, and gender among gynecologic oncology leaders at ACGME-accredited fellowship programs

Jul 26, 2026

The authors aimed to assess the demographics, opinions on diversity and inclusion, and barriers to representation among gynecologic oncology leaders in ACGME-accredited fellowship programs in the U.S. Their findings revealed a predominance of White leaders and highlighted systemic barriers to diversity, suggesting that early mentorship and leadership development initiatives are crucial for creating more equitable pathways in the field.

<em>KAT6B/A::KANSL1</em> uterine sarcoma - A case with recurrences following uterine morcellation and the development of primary cell line model

Jul 26, 2026

The authors investigate the characteristics and recurrence patterns of KAT6B/A::KANSL1 uterine sarcoma, particularly in relation to uterine morcellation during surgery. They present two case studies, highlighting the challenges of establishing primary cell line models from these tumors, which ultimately do not retain estrogen receptor expression despite the tumors being strongly ER-positive. The findings suggest that morcellation may elevate the risk of recurrence in this type of sarcoma.

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against <em>ERBB2</em>-mutated cervical carcinomas with low HER2 expression

Jul 25, 2026

The authors investigate the efficacy of trastuzumab deruxtecan (T-DXd) as a targeted therapy for cervical carcinomas with somatic HER2 mutations, specifically focusing on those with low HER2 expression. Their findings demonstrate that T-DXd significantly outperforms control treatments in both in vitro and in vivo models of HER2-S310F-mutated cervical cancer, suggesting it could be a promising therapeutic option for patients with recurrent cervical cancer harboring ERBB2 mutations.

Durable response to pembrolizumab plus axitinib in platinum-resistant ovarian clear cell carcinoma: A case report

Jul 25, 2026

This case report investigates the efficacy of combining pembrolizumab, an immune checkpoint inhibitor, with axitinib, a VEGFR-targeted therapy, in treating a 39-year-old woman with platinum-resistant ovarian clear cell carcinoma (OCCC). The authors aim to explore the potential of this combination to achieve durable disease control in a setting where treatment options are limited. The patient demonstrated sustained radiographic improvement for approximately 23 months, suggesting that this therapeutic strategy may offer meaningful benefits for selected patients with OCCC.